Grant: Knowledge Synthesis Grant
McMaster University
$100,000.00
Common methods for the reporting and application of minimally important differences in randomized controlled trials evaluating patient reported outcomes: A systematic survey
EF 2015-16
Résumé
Background: Patient reported outcomes (PROs) provide patients’ perspectives on treatment benefits and harms and are often the outcomes of most importance to patients. PROs play a pivotal role in bringing forth patients’ values and preferences to evidence-based health care. In recent years, investigators and clinicians have placed a strong emphasis on the use of PROs as endpoints in clinical trials, and data obtained from PROs in trials are increasingly used to inform patient-centered care, clinical decision-making and health policy. Despite the impact of PROs on decision-making, the ability to determine from PRO results whether the effects of interventions are trivial, small but important, or substantial remains a challenge. The minimal important difference (MID), which provides a measure of the smallest change in a PRO that patients would perceive as important, addresses this gap.
Objective: The present study aims to empirically evaluate the frequency and features of MIDs used in randomized controlled trials (RCTs) assessing PROs to evaluate the impact of interventions on chronic medical and psychiatric conditions in adults. Specifically, our objectives are to: 1) assess how frequently MIDs are used in RCTs assessing PROs; 2) identify the proportion of trials using an MID for sample size calculations or to interpret treatment effects on PROs; 3) describe methods used to ascertain the reported MID; 4) identify trial characteristics associated with reporting of an MID; and 5) document the credibility of reported MIDs
Methods: We will search MEDLINE, EMBASE, CENTRAL and PsycINFO to identify original reports of RCTs published in 2014 that evaluate the impact of interventions on at least one PRO in patients with a chronic medical or psychiatric condition. A team of reviewers will screen identified citations, review full texts of potentially eligible citations, and extract relevant data from a random sample of eligible studies. We will abstract data pertaining to trial characteristics, methodological quality, characteristics of candidate PROs, as well as characteristics and information regarding the reporting and application of the MID.
Core Expertise: Our multi-disciplinary team is comprised of knowledge users and researchers with extensive experience with PRO research, MID methodology, clinical trials and systematic reviews, and knowledge translation methods. We represent and provide direct links to key knowledge users including the GRADE Working Group, Cochrane Collaboration, Public Health Agency of Canada, and the Canadian Agency for Drugs and Technologies in Health. Collectively, these organizations provide opportunities for disseminating our findings to an international network of clinical trialists, systematic reviewers and guideline developers.
Significance: Our systematic survey will be the first to comprehensively document the frequency of MID reporting in RCTs measuring PROs. The implications of this empirical study are far-reaching, and will be of great importance to a number of stakeholders, including individuals and organizations that use PRO instruments in research and to inform clinical decision-making. Increased use and improved interpretation of PROs in trials using the MID will better inform healthcare decisions and evidence-based guidelines, ultimately enhancing quality of care and patient outcomes.
Programme
Knowledge Synthesis Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
346790
Name
Guyatt Gordon H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Knowledge Synthesis Grant
Projecttitle
Common methods for the reporting and application of minimally important differences in randomized controlled trials evaluating patient reported outcomes: A systematic survey
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Knowledge Synthesis Grant
Keyworddelim
Clinical Practice Guidelines; Clinical Trials; Minimally Important Difference; Patient Reported Outcomes; Quality Of Life; Systematic Reviews
Abstract
<html>
<body>
<p>
<strong>Background:</strong> Patient reported outcomes (PROs) provide patients’ perspectives on treatment benefits and harms and are often the outcomes of most importance to patients. PROs play a pivotal role in bringing forth patients’ values and preferences to evidence-based health care. In recent years, investigators and clinicians have placed a strong emphasis on the use of PROs as endpoints in clinical trials, and data obtained from PROs in trials are increasingly used to inform patient-centered care, clinical decision-making and health policy. Despite the impact of PROs on decision-making, the ability to determine from PRO results whether the effects of interventions are trivial, small but important, or substantial remains a challenge. The minimal important difference (MID), which provides a measure of the smallest change in a PRO that patients would perceive as important, addresses this gap.</p>
<p>
<strong>Objective:</strong> The present study aims to empirically evaluate the frequency and features of MIDs used in randomized controlled trials (RCTs) assessing PROs to evaluate the impact of interventions on chronic medical and psychiatric conditions in adults. Specifically, our objectives are to: 1) assess how frequently MIDs are used in RCTs assessing PROs; 2) identify the proportion of trials using an MID for sample size calculations or to interpret treatment effects on PROs; 3) describe methods used to ascertain the reported MID; 4) identify trial characteristics associated with reporting of an MID; and 5) document the credibility of reported MIDs</p>
<p>
<strong>Methods:</strong> We will search MEDLINE, EMBASE, CENTRAL and PsycINFO to identify original reports of RCTs published in 2014 that evaluate the impact of interventions on at least one PRO in patients with a chronic medical or psychiatric condition. A team of reviewers will screen identified citations, review full texts of potentially eligible citations, and extract relevant data from a random sample of eligible studies. We will abstract data pertaining to trial characteristics, methodological quality, characteristics of candidate PROs, as well as characteristics and information regarding the reporting and application of the MID.</p>
<p>
<strong>Core Expertise:</strong> Our multi-disciplinary team is comprised of knowledge users and researchers with extensive experience with PRO research, MID methodology, clinical trials and systematic reviews, and knowledge translation methods. We represent and provide direct links to key knowledge users including the GRADE Working Group, Cochrane Collaboration, Public Health Agency of Canada, and the Canadian Agency for Drugs and Technologies in Health. Collectively, these organizations provide opportunities for disseminating our findings to an international network of clinical trialists, systematic reviewers and guideline developers.</p>
<p>
<strong>Significance:</strong> Our systematic survey will be the first to comprehensively document the frequency of MID reporting in RCTs measuring PROs. The implications of this empirical study are far-reaching, and will be of great importance to a number of stakeholders, including individuals and organizations that use PRO instruments in research and to inform clinical decision-making. Increased use and improved interpretation of PROs in trials using the MID will better inform healthcare decisions and evidence-based guidelines, ultimately enhancing quality of care and patient outcomes.</p>
</body>
</html>
Competitiondate
201601
Approvedterm2
1 yr 0 mth
Pinamesdelim
Guyatt, Gordon H; Ebrahim, Shanil
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~